Sitagliptin in Non-Diabetic Patients Undergoing General Surgery
Completed · Phase 4 · Has a placebo group
Conditions studied: Hyperglycemia
In brief
The purpose of this study is to compare sitagliptin with a placebo for the prevention of high glucose after general surgery.
Key facts
- Study ID
- NCT02741687
- Run by
- Emory University
- People needed
- 80
- Starts
- 2016-06-01
- Expected to finish
- 2017-04-01
- Last updated by the study team
- 2018-06-27
Who can join
Age: 18 and older, up to 80. Sex: any. Healthy volunteers: not accepted.
You may qualify if…
- Undergoing non-cardiac surgery
- No previous history of diabetes or hyperglycemia
- Fasting blood glucose level of <126 mg/dl
- Blood glucose <126mg/dl at the time of randomization (could occur at any time of the day)
You may not qualify if…
- History of hyperglycemia (blood glucose equal to or above 126 mg/dl or HbA1C greater than 6.5%) or previous treatment with oral antidiabetic agents or insulin
- Patients undergoing cardiac surgery
- Patients anticipated to require ICU care following surgery
- Severely impaired renal function (GFR < 30 ml/min) or clinically significant hepatic failure
- Moribund patients and those at imminent risk of death (brain death or cardiac standstill)
- Patients with gastrointestinal obstruction or adynamic ileus or those expected to require gastrointestinal suction
- Patients with clinically relevant pancreatic or gallbladder disease
- Treatment with oral (> 5 mg/day) or injectable corticosteroid
- Mental condition rendering the subject unable to understand the nature, scope, and possible consequences of the study
- Pregnancy or breast-feeding at time of enrollment
Where it is running
- Grady Memorial Hospital — Atlanta, Georgia, United States
- Emory University Hospital Midtown — Atlanta, Georgia, United States
Full record on ClinicalTrials.gov
Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.